# Ventoux Biosciences

Modulating Fibrosis, Restoring Function 

- Canonical URL: https://wefunder.com/ventoux.biosciences
- Entity ID: wefunder:company:148895
- Last updated: 2026-07-21T23:54:16Z
- Generated at: 2026-07-22T23:45:34Z

## Quick facts
- Founded by a Dupuytren's patient to transform care for millions with immune-fibrotic diseases
- Targeting Dupuytren's and Spinal Cord Injury with VEN-201, a novel, immune-fibrotic modulator
- VEN-201 rebalances the immune system to reduce fibrosis and activate repair
- 2025 Pre-Clinical Biopharmaceutical Company of the Year Winner, by GHP Biotechnology Awards
- $4.3B Dupuytren's disease market, >3x larger than Rheumatoid Arthritis - no approved treatments
- SCI: ~$10B annually, VEN-201 targets fibrosis, addressing the key market opportunity in recovery
- Strong IP: Broad immune-fibrotic patent to 2044, global filings plus key provisional filings

## Active fundraises
- wefunder:fundraise:104663: 4(a)(6) open (USD)

## Team
- Kurt Harrington (Founder, CEO)
- Kenneth Lipson (Chief Scientific Officer, VP Corporate Strategy)
- Laxma Reddy (VP, Product Development )